ResearchAndMarkets.com has added a report forecasting approximately 16% compound annual growth in the chondrosarcoma market across the seven major markets through 2036. The market was valued at about $15 million in 2025, when the United States accounted for roughly $10 million. Approximately 2,300 incident cases were recorded across the seven markets, with conventional chondrosarcoma representing about 80% of cases and IDH mutations present in roughly 50% to 70% of tumors. Surgery remains the primary curative approach for localized disease, while chemotherapy and radiotherapy have limited effectiveness in conventional chondrosarcoma and no drug is specifically approved for the disease. The report highlights Servier's ivosidenib, an IDH1 inhibitor in the Phase III CHONQUER study, and Inhibrx's INBRX-109, or ozekibart, a tetravalent DR5 agonistic antibody in a potentially registration-enabling Phase II study. It examines epidemiology, treatment patterns, clinical development, market access, reimbursement, pricing and forecasts across the United States, Germany, France, Italy, Spain, the United Kingdom and Japan.